Sermorelin 5mg
$49.99
Sermorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH) that is commonly used to evaluate and enhance endogenous growth hormone production. Research interest in sermorelin stems from its potential roles in promoting bone density, minimizing scar formation, mitigating cognitive decline associated with dementia, and reducing seizure occurrence.
$49.99
$49.99
Peptide Capsules
Purchase Peptides
Purchase Blends
Overview
Sermorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH) that stimulates the pituitary gland to increase endogenous growth hormone (GH) secretion. Clinically, it has been used both as a diagnostic tool for assessing pituitary function and as a therapeutic option for individuals with growth hormone deficiency. Unlike direct recombinant GH administration, sermorelin engages the hypothalamic–pituitary axis, supporting a more physiologically regulated release of GH and its downstream mediator, insulin-like growth factor 1 (IGF-1).
In addition to its established use in growth hormone regulation, research suggests wider therapeutic potential. Studies indicate that sermorelin may help improve bone density through the anabolic effects of GH and IGF-1 on skeletal tissue. It has also been linked to reduced fibrosis and scarring due to enhanced tissue repair and collagen remodeling. Emerging findings further point to possible neuroprotective effects, including a role in mitigating cognitive decline associated with aging and reducing seizure activity.
Overall, sermorelin is recognized as a clinically relevant peptide with applications that extend beyond endocrinology, making it a subject of interest in fields such as regenerative medicine and neuroscience.
Sermorelin: Structure
Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg
Molecular Formula: C₁₄₉H₂₄₆N₄₄O₄₂S
Molecular Weight: 3357.933 g/mol
PubChem CID: 16129620
Source: PubChem
Sermorelin : Research
Sermorelin in Children with Idiopathic GHD
Sermorelin is a 29–amino acid synthetic analogue of growth hormone–releasing hormone (GHRH) and represents the shortest peptide with full biological activity. When administered intravenously or subcutaneously, it stimulates growth hormone release from the anterior pituitary. Intravenous sermorelin at 1 μg/kg is considered a rapid and relatively specific diagnostic tool for growth hormone deficiency (GHD), producing fewer false positives than other stimulation tests. In adults, combining intravenous sermorelin with arginine enhances diagnostic specificity, though normal responses may still occur in patients with hypothalamic dysfunction, necessitating additional confirmatory testing.
Therapeutically, once-daily subcutaneous dosing of 30 μg/kg, typically at bedtime, has shown effectiveness in some prepubertal children with idiopathic GHD, with sustained improvements in growth velocity over 12 to 36 months and evidence of catch-up growth in many cases. Children with delayed bone and height age appear to respond particularly well. However, the long-term impact on final adult height remains uncertain. Comparisons suggest sermorelin may be less potent than somatropin for increasing height velocity at equivalent dosing schedules.
Sermorelin is generally well tolerated, with mild side effects such as transient facial flushing and injection-site discomfort. Overall, it is useful both as a diagnostic agent for GHD and as a treatment option in selected pediatric patients.
GHRH Antagonists & Aging Physiology
Both insufficient and excessive growth hormone (GH) are linked to higher mortality and health risks. While GH replacement can cause complications in healthy individuals, isolated GH deficiency has been associated with extended lifespan. In this study, the effects of the GHRH receptor antagonist MZ-5-156 were tested in SAMP8 mice, a model prone to cognitive decline and shortened lifespan. Daily injections of MZ-5-156 (10 μg/mouse) beginning at 10 months of age enhanced telomerase activity, reduced oxidative stress in the brain, and improved cognitive performance and balance, though muscle strength remained unchanged. Cognitive benefits were observed after 2–4 months of treatment but diminished after 7 months. Treated mice lived on average 8 weeks longer, and tumor incidence fell significantly from 10% to 1.7%, without extending maximal lifespan. These findings suggest that GHRH antagonism can improve certain aspects of aging, particularly cognition, stress resistance, and telomerase activity.
Sermorelin : Scientific Journal & Authors
William A. Banks one of the authors of ” Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice”. He is affiliated with the Division of Gerontology and Geriatric Medicine at the Geriatrics Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System in Seattle.
William A. Banks is noted as one of the key researchers who contributed to the scientific investigation and development of Sermorelin. His mention here does not imply endorsement, promotion, or association with the sale or use of this compound. There is no formal connection between Licensed Peptides and Dr. Banks. The reference is provided solely to acknowledge and credit his contributions to the scientific research surrounding this peptide.
Referenced Citations
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products available on this website are intended solely for in-vitro research purposes (Latin: “in glass”), meaning they are used in experiments conducted outside a living organism. These products are not medicines or drugs, have not been evaluated or approved by the U.S. Food and Drug Administration (FDA), and are not intended to diagnose, treat, cure, or prevent any disease or medical condition. Any administration to humans or animals, whether by ingestion, injection, or other means, is strictly prohibited by law.
Test
Storage Instructions:
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.
Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you’re ready to reconstitute it with bacteriostatic water.
Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4C (39F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.
However, for longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80C (-112F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide’s stability.
For further information on proper storage techniques, click the link below: